GLP-1 receptor distribution
However, numerous gaps in our knowledge of CV outcomes in T2D remain, and we believe that RWE studies can have a role here, by complementing CVOTs with supporting evidence where data generation in a RCT would not be feasible
Finally, semaglutide may also have an effect on the body's metabolism
This includes diseases such as cardiovascular disease, type 2 diabetes, high blood pressure, sleep apnea, joint problems, and certain types of cancer
If you are a business facing a lawsuit by Novo Nordisk or another pharmaceutical company attempting to police your offering of compounded weight-loss products, please reach out to our team